Evidence map›Paper›PMID 38658171›Full record

SynthesisWorld journal of surgery2024

Cytoreductive surgery plus hyperthermic intraoperative peritoneal chemotherapy for people with peritoneal metastases from colorectal, ovarian or gastric origin: A systematic review of randomized controlled trials.

Kurinchi Gurusamy, Jeffrey Leung, Claire Vale, Danielle Roberts, Audrey Linden, Xiao Wei Tan, Priyal Taribagil, Sonam Patel, Elena Pizzo, Brian Davidson and 3 more

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Intraperitoneal chemotherapy for gastric cancer.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Kurinchi GurusamyUniversity College London, London, UK.
Jeffrey LeungUniversity College London, London, UK.ORCID 0000-0003-2348-9702
Claire ValeUniversity College London, London, UK.
Danielle RobertsUniversity College London, London, UK.
Audrey LindenUniversity College London, London, UK.
Xiao Wei TanUniversity College London, London, UK.
Priyal TaribagilUniversity College London, London, UK.
Sonam PatelUniversity College London, London, UK.
Elena PizzoUniversity College London, London, UK.
Brian DavidsonUniversity College London, London, UK.
Mark SaundersThe Colorectal and Peritoneal Oncology Centre, Christie NHS Foundation Trust, London, UK.
Omer AzizThe Colorectal and Peritoneal Oncology Centre, Christie NHS Foundation Trust, London, UK.
Sarah T O'DwyerThe Colorectal and Peritoneal Oncology Centre, Christie NHS Foundation Trust, London, UK.
University College London · GBUniversity of Manchester · GBThe Christie NHS Foundation Trust · GB

Funding

Department of Health 17/135/02Medical Research Council MC_UU_00004/06National Institute for Health and Care Research Program HTA Project: 17/135/02United Kingdom Research and Innovation (UKRI) Medical Research Council MC_UU_00004/06
6 · The paper itself

Abstract

backgroundThere is uncertainty in the relative benefits and harms of hyperthermic intraoperative peritoneal chemotherapy (HIPEC) when added to cytoreductive surgery (CRS) +/- systemic chemotherapy or systemic chemotherapy alone in people with peritoneal metastases from colorectal, gastric, or ovarian cancers.

methodsWe searched randomized controlled trials (RCTs) in the medical literature until April 14, 2022 and applied methods used for high-quality systematic reviews.

findingsWe included a total of eight RCTs (seven RCTs included in quantitative analysis as one RCT did not provide data in an analyzable format). All comparisons other than ovarian cancer contained only one trial. For gastric cancer, there is high uncertainty about the effect of CRS + HIPEC + systemic chemotherapy. For stage III or greater epithelial ovarian cancer undergoing interval cytoreductive surgery, CRS + HIPEC + systemic chemotherapy probably decreases all-cause mortality compared to CRS + systemic chemotherapy. For colorectal cancer, CRS + HIPEC + systemic chemotherapy probably results in little to no difference in all-cause mortality and may increase the serious adverse events proportions compared to CRS +/- systemic chemotherapy, but probably decreases all-cause mortality compared to fluorouracil-based systemic chemotherapy alone.

interpretationThe role of CRS + HIPEC in gastric peritoneal metastases is uncertain. CRS + HIPEC should be standard of care in women with stage III or greater epithelial ovarian cancer undergoing interval CRS. CRS + systemic chemotherapy should be standard of care for people with colorectal peritoneal metastases, with HIPEC given only as part of a RCT focusing on subgroups and regimes. PROSPERO REGISTRATION: CRD42019130504.

Indexed as

Colorectal NeoplasmsCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyOvarian NeoplasmsPeritoneal NeoplasmsRandomized Controlled Trials as TopicStomach NeoplasmsCombined Modality TherapyFemaleHumansHyperthermia, Inducedcost‐effectiveness analysiscost‐utility analysisevidence‐based medicinehyperthermic intraoperative peritoneal chemotherapymeta‐analysisperitoneal metastasesprobabilistic sensitivity analysissystematic reviewvalue of information analysis

Identifiers

PMID38658171
PMCPMC7617159
OpenAlexW4395466602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.